ReviewMolecular medicine reports2025
Matrix metalloproteinase‑9 in hemorrhagic transformation after acute ischemic stroke (Review).
Review in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Clinical Utility of Circulating Biomarkers for Diagnosis and Prognosis of Acute Stroke in the Emergency Department: A Narrative Review from Current Evidence to Clinical Implementation.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Epigenetic Regulation of the NET Formation-Blood-Brain Barrier Axis in Ischemic Stroke: Mechanisms, Therapeutic Targets and Translational Perspectives.Neurology international · 2026Review
- Venous Blood Cell Ratios as Predictors of Reperfusion Outcomes in Ischemic Stroke: A Systematic Review and Meta-analysis.Neurology and therapy · 2026Article
- Correlations of thrombus MMP-9 level with clinical characteristics and inflammatory markers in acute ischemic stroke.BMC neurology · 2026Article
- Is there a role for apolipoprotein E in perinatal brain injury?Molecular and cellular pediatrics · 2026Review
- Integrative transcriptomic analysis identifies an oxidative stress-associated diagnostic signature for myocardial infarction.Journal of thrombosis and thrombolysis · 2026Article
- Recent advances in stroke biomarkers - implications for prognosis and treatment.Current opinion in neurology · 2026Review
- BMSC-Derived Exosomal miR-21a-5p Ameliorates Blood-Brain Barrier Injury and Hemorrhagic Transformation.Molecular neurobiology · 2026Article
- Verification of the predictive value of EV-associated biomarkers MMP9 and CEACAM1 in rehabilitation of ischemic stroke.Extracellular vesicles and circulating nucleic acids · 2026Article
- Advances in genetics and multi-omics for ischemic stroke: from pathogenesis to clinical translation.Frontiers in genetics · 2026Review
- Dynamic trajectories of inflammatory biomarkers and post-stroke cognitive impairment: a comprehensive review of neuroimmune mechanisms, longitudinal modeling, and clinical translation.Frontiers in neurology · 2026Review
- Inflammation-centered neurovascular-immune-metabolic remodeling in ischemic stroke: stage-dependent mechanisms, regulated cell death, and therapeutic translation.Frontiers in immunology · 2026Review
- Banxia-Baizhu-Tianma Decoction Combined with Acupuncture for Cerebral Ischemic Stroke: A Narrative Review.International journal of general medicine · 2026Review
- Article
- Apelin-13 Attenuates Blood-Brain Barrier Dysfunction Following Intracerebral Hemorrhage via Targeting the Keap1/Nrf2 Signaling.CNS neuroscience & therapeutics · 2025Article
- Mfsd2a-Targeted Therapy for Ischemic Stroke: Mechanisms, Evidence, and Future Prospects.CNS neuroscience & therapeutics · 2025Review
- An Integrated Microfluidic System for One-Stop Multiplexed Exosomal PD-L1 and MMP9 Automated Analysis with Deep Learning Model YOLO.Micromachines · 2025Article
- Targeting CX3CR1 Signaling Dynamics: A Critical Determinant in the Temporal Regulation of Post-Stroke Neurorepair.Brain sciences · 2025Review
- Safety and efficacy of intravenous tPA after successful thrombectomy for large vessel occlusion: a retrospective study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemorrhagic transformation (HT) is a devasting complication following acute ischemic stroke with high morbidity and mortality. The pathogenesis of HT mainly involves ischemia‑reperfusion‑induced oxidative stress, neuroinflammation, thrombolytic therapy‑associated toxicity and, most critically, blood‑brain barrier (BBB) disruption. Matrix metalloproteinase‑9 (MMP‑9) serves as a critical mediator of HT through degrading extracellular matrix components and disrupting tight junction proteins, thereby compromising BBB integrity. Thus, elaborating the underlying molecular mechanisms of MMP‑9 in destroying BBB and promoting HT is essential to improve the outcome of ischemic stroke patients. Furthermore, to provide beneficial insights for the treatment of ischemic stroke, precise understanding of the potential role of MMP‑9 as a biomarker and treatment target to predict and ameliorate the risk of HT is also necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.